康泰医学
(300869)
| 流通市值：32.71亿 | | | 总市值：51.87亿 |
| 流通股本：2.53亿 | | | 总股本：4.02亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 333,885,288.03 | 211,789,804.52 | 99,175,164.46 | 746,902,140.39 |
| 营业收入 | 333,885,288.03 | 211,789,804.52 | 99,175,164.46 | 746,902,140.39 |
| 二、营业总成本 | 336,662,644.47 | 212,974,691.76 | 102,176,199.13 | 568,889,907.42 |
| 营业成本 | 167,266,311.47 | 106,962,931.79 | 50,192,307.62 | 316,821,601.08 |
| 税金及附加 | 6,524,487.08 | 4,532,617.97 | 2,799,974.12 | 12,853,512.08 |
| 销售费用 | 56,438,909.91 | 36,429,656.3 | 16,173,587.84 | 117,690,546.98 |
| 管理费用 | 26,684,621.96 | 17,826,736.72 | 10,796,696.87 | 41,778,164.98 |
| 研发费用 | 83,429,418.51 | 56,055,044.05 | 27,140,047.87 | 110,600,251.24 |
| 财务费用 | -3,681,104.46 | -8,832,295.07 | -4,926,415.19 | -30,854,168.94 |
| 其中:利息费用 | - | - | - | 45,103,342.44 |
| 其中:利息收入 | - | - | - | 81,178,482.31 |
| 加:公允价值变动收益 | 916,579.69 | 1,548,798.82 | 562,915.78 | 2,023,602.74 |
| 加:投资收益 | 15,360,687.14 | 11,098,894.68 | 7,695,776.25 | 11,468,491.81 |
| 资产处置收益 | 166,241.78 | 7,936.7 | -28,003.62 | -67,801.93 |
| 资产减值损失(新) | -8,762,780.34 | -6,129,554.46 | -3,190,081.7 | -39,110,548.5 |
| 信用减值损失(新) | -1,186,588.14 | -1,418,946.35 | -670,641.33 | 1,080,618.72 |
| 其他收益 | 6,755,701.03 | 3,984,036.36 | 1,438,713.74 | 33,327,457.41 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 10,472,484.72 | 7,906,278.51 | 2,807,644.45 | 186,734,053.22 |
| 加:营业外收入 | 1,376,087.09 | 1,181,427.54 | 598,027.08 | 476,325.73 |
| 减:营业外支出 | 690,120.83 | 583,373.73 | 286,452.02 | 1,084,553.34 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 11,158,450.98 | 8,504,332.32 | 3,119,219.51 | 186,125,825.61 |
| 减:所得税费用 | 1,255,523.12 | 337,211.53 | -1,232,715.6 | 20,359,839.81 |
| 六、净利润 | 9,902,927.86 | 8,167,120.79 | 4,351,935.11 | 165,765,985.8 |
| 持续经营净利润 | 9,902,927.86 | 8,167,120.79 | 4,351,935.11 | 165,765,985.8 |
| 归属于母公司股东的净利润 | 9,902,927.86 | 8,167,120.79 | 4,351,935.11 | 165,765,985.8 |
| (一)基本每股收益 | 0.02 | 0.02 | 0.01 | 0.41 |
| (二)稀释每股收益 | - | - | 0 | 0.4 |
| 八、其他综合收益 | -713,854.79 | 78,993.98 | -135,263.53 | 761,799.6 |
| 归属于母公司股东的其他综合收益 | -713,854.79 | 78,993.98 | -135,263.53 | 761,799.6 |
| 九、综合收益总额 | 9,189,073.07 | 8,246,114.77 | 4,216,671.58 | 166,527,785.4 |
| 归属于母公司股东的综合收益总额 | 9,189,073.07 | 8,246,114.77 | 4,216,671.58 | 166,527,785.4 |
| 公告日期 | 2024-10-28 | 2024-08-30 | 2024-04-29 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |